Advertisement
ViroPharma also announced that William Roberts, vice president, corporatecommunications of ViroPharma will present at the 15th Annual BioCenturyNewsmakers in the Biotech Industry Conference at 1:30 P.M. ET on Thursday,September 4, 2008. The conference is being held at the Millennium BroadwayHotel in New York.
Advertisement
Mr. Roberts also will present at the UBS Global Life Sciences Conferenceat 8:00 A.M. ET on Tuesday, September 23, 2008. The conference is being heldat the Grand Hyatt in New York.
ViroPharma's presentations will be webcast live for investors throughhttp://www.viropharma.com and available for a period of 14 days following theconferences.
About ViroPharma Incorporated
ViroPharma Incorporated is committed to the development andcommercialization of products that address serious diseases treated byphysician specialists and in hospital settings. ViroPharma commercializesVancocin(R) approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile andenterocolitis caused by Staphylococcus aureus, including methicillin-resistantstrains (for prescribing information, please download the package insert athttp://www.viropharma.com/Products.aspx). ViroPharma currently focuses itsdrug development activities in infectious diseases including cytomegalovirus(CMV) and non-toxigenic C. difficile (NTCD). For more information onViroPharma, visit the Company's website at http://www.viropharma.com.
SOURCE ViroPharma Incorporated
